Overview
10-20% of patients with ALS have anti-NRIP autoantibody and the titer of anti-NRIP autoantibody is correlated with motor functional decline and mortality in ALS. The PALADIN2 clinical trial is a single arm study, which intends to enroll 20 ALS patients having anti-NRIP autoantibody in plasma. Patients will receive 3 courses of plasmapheresis per 3 months in order to maintain low concentration of anti-NRIP autoantibody in plasma. The study will follow up these patients for another 6 months after plasmapheresis. This project will potentially confirm the efficacy and safety of plasmapheresis for ALS patients having anti-NRIP autoantibody.
Eligibility
Inclusion Criteria:
- ALS patients above 20-year-old who have anti-NRIP autoantibody in plasma
- Agree to receive plasmapheresis treatment
- Agree to participate in the study and receive serial examinations
Exclusion Criteria:
- Under permanent ventilator support
- Cannot receive plasmapheresis treatment or serial examinations
- Under pregnancy
- Blood fibrinogen level below 50 mg/dl
- Belong to special subtype of ALS, such as primary lateral sclerosis, progressive muscular atrophy, flail arm syndrome, flail leg syndrome.
